Role of testosterone in the pathogenesis, progression, prognosis and comorbidity of men with chronic kidney disease

Therapeutic Apheresis and Dialysis

Volumn 18, Issue 3, 2014, Pages 220-230

  Dousdampanis, Periklis ^a   Trigka, Konstantina ^a   Fourtounas, Costas ^b   Bargman, Joanne M ^c  

^a Hemodialysis Unit Kyanos Stavros Patras   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Anemia; Cardiovascular disease; Chronic kidney disease; Hypertension; Osteoporosis; Testosterone

Indexed keywords

TESTOSTERONE;

ANDROGEN DEFICIENCY; ANEMIA; BLOOD PRESSURE REGULATION; BONE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL STUDY; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; EXPERIMENTAL STUDY; HORMONE ACTION; HUMAN; KIDNEY FIBROSIS; KIDNEY TUBULE PRESSURE; MINERAL DEFICIENCY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ANIMAL; COMPLICATION; DEFICIENCY; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; PATHOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; DISEASE PROGRESSION; HUMANS; HYPOGONADISM; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; TESTOSTERONE;

EID: 84903306385     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12101     Document Type: Review

References (129)

1. Schaefer F, Mehls O, Ritz E. New insights into endocrine disturbances of chronic renal failure. Miner Electrolyte Metab 1992;18:169-173.
2. Quan A, Chakravarty S, Chen JK etal. Androgens augment proximal tubule transport. Am J Physiol Renal Physiol 2004;287:F452-459.
3. Metcalfe D, Leslie JA, Campbell MT, Meldrum DR, Hile KL, Meldrum KK. Testosterone exacerbates obstructive renal injury by stimulating TNF-alpha production and increasing proapoptotic and profibrotic signaling. Am J Physiol Endocrinol Metab 2008;294:E435-443.
4. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000;11:319-329.
5. Jafar TH, Schmid CH, Stark P etal. The rate of progression of renal disease may not be slower in woman compared with men: a patient level meta-analysis. Nephrol Dial Transplant 2003;18:2047-2053.
6. Cho MH, Jung KJ, Jang HS, Kim JI, Park KM. Orchiectomy attenuates kidney fibrosis after ureteral obstruction by reduction of oxidative stress in mice. Am J Nephrol 2012;35:7-16.
7. Albaaj F, Sivalingham M, Haynes P etal. Prevalence of hypogonadism in male patients with renal failure. Postgrad Med J 2006;82:693-696.
8. Carrero JJ, Bárány P, Yilmaz MI etal. Testosterone deficiency is a cause of anemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transplant 2012;27:709-715.
9. Yilmaz MI, Sonmez A, Qureshi AR etal. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol 2011;6:1617-1625.
10. Carrero JJ, Qureshi AR, Parini P etal. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009;20:613-620.
11. Holley JL. The hypothalamic-pituitary axis in men and women with chronic kidney disease. Adv Chronic Kidney Dis 2004;11:337-341.
12. Spratt DI, Bigos ST, Beitins I, Cox P, Longcope C, Orav J. Both hyper- and hypogonadotropic hypogonadism occur transiently in acute illness: bio-and immunoactive gonadotropins. J Clin Endocrinol Metab 1992;75:1562-1570.
13. Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest 2005;28(3 Suppl):14S-22.
14. Bacchetta J, Plotton I, Ranchin B etal. Precocious puberty and unlicensed paediatric drugs for severe hyperparathyroidism. Nephrol Dial Transplant 2009;24:2595-2598.
15. Grossmann M, Gianatti EJ, Zajac JD. Testosterone and type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010;17:247-256.
16. Veldhuis JD, Wilkowski MJ, Zwart AD etal. Evidence for attenuation of hypothalamic gonadotropin-releasing hormone (GnRH) impulse strength with preservation of GnRH pulse frequency in men with chronic renal failure. J Clin Endocrinol Metab 1993;76:648-654.
17. Schaefer F, Vogel M, Kerkhoff G, Woitzik J, Daschner M, Mehls O. Experimental uremia affects hypothalamic amino acid neurotransmitter milieu. J Am Soc Nephrol 2001;12:1218-1227.
18. Dunkel L, Raivio T, Laine J, Holmberg C. Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney Int 1997;51:777-784.
19. Mitchell R, Bauerfeld C, Schaefer F, Schärer K, Robertson WR. Less acidic forms of luteinizing hormone are associated with lower testosterone secretion in men on haemodialysis treatment. Clin Endocrinol (Oxf) 1994;4:65-73.
20. Cheung CY. Prolactin suppresses luteinizing hormone secretion and pituitary responsiveness to luteinizing hormone-releasing hormone by a direct action at the anterior pituitary. Endocrinology 1983;113:632-638.
21. McNeilly AS. Prolactin and the control of gonadotropin secretion in the female. J Reprod Fertil 1980;58:537-549.
22. Schmidt A, Luger A, Hörl WH. Sexual hormone abnormalities in male patients with renal failure. Nephrol Dial Transplant 2002;17:368-371.
23. Feinstein EI, Wanner C, Böhler J, Hörl WH. Endocrine and metabolic disorders following kidney transplantation. Am J Nephrol 1992;12:363-368.
24. Tokgoz B, Utas C, Dogukan A etal. Effects of long-term erythropoietin therapy on the hypothalamo-pituitary-testicular axis in male CAPD patients. Perit Dial Int 2001;21:448-454.
25. van Eps C, Hawley C, Jeffries J etal. Changes in serum prolactin, sex hormones and thyroid function with alternate nightly nocturnal home dialysis. Nephrology (Carlton) 2012;17:42-47.
26. Handelsman DJ. Hypothalamic-pituitary gonadal dysfunction in renal failure, dialysis and renal transplantation. Endocr Rev 1985;6:151-182.
27. Handelsman DJ, Dong Q. Hypothalamo- pituitary gonadal axis in chronic renal failure. Endocrinol Metab Clin North Am 1993;22:145-161.
28. Khoury S, Yarows SA, O'Brien TK, Sowers JR. Ambulatory blood pressure monitoring in a nonacademic setting. Effects of age and sex. Am J Hypertens 1992;5:616-623.
29. Wiinberg N, Hoegholm A, Christensen HR etal. 24-h Ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. Am J Hypertens 1995;8(10Pt 1):978-986.
30. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001;37:1199-1208.
31. Reckelhoff JF, Samsell L, Dey R, Racusen L, Baylis C. The effect of aging on glomerular hemodynamics in the rat. Am J Kidney Dis 1992;20:70-75.
32. Reckelhoff JF, Zhang H, Granger JP. Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension 1998;31(1 Pt 2):435-439.
33. Reckelhoff JF, Yanes LL, Iliescu R, Fortepiani LA, Granger JP. Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease. Am J Physiol Renal Physiol 2005;289:F941-948.
34. Chen YF, Naftilan AJ, Oparil S. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension 1992;19:456-463.
35. Song J, Kost CK, Martin DS. Androgens potentiate renal vascular responses to angiotensin II via amplification of the Rho kinase signaling pathway. Cardiovasc Res 2006;72:456-463.
36. Song J, Eyster KM, Kost CK Jr, Kjellsen B, Martin DS. Involvement of protein kinase C-CPI-17 in androgen modulation of angiotensin II-renal vasoconstriction. Cardiovasc Res 2010;85:614-621.
37. Mukai Y, Shimokawa H, Matoba T etal. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutical target in hypertension. FASEB J 2001;15:1062-1064.
38. Svartberg J. Review: epidemiology: testosterone and the metabolic syndrome. Int J Impot Res 2007;19:124-128.
39. Svartberg J, von Muhlen D, Schirmer H, Barrett-Connor E, Sundfjord J, Jorde R. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Eur J Endocrinol 2004;150:65-71.
40. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007;92:3844-3853.
41. Silbiger S, Neugarten J. Gender and human chronic renal disease. Gend Med 2008;5(Suppl A):3S-S10.
42. Ji H, Menini S, Mok K etal. Gonadal steroid regulation of renal injury in renal wrap hypertension. Am J Physiol 2005;288:F513-520.
43. Alexander BT, Cockrell KL, Rinewalt AN, Herrington JN, Granger JP. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol 2001;280:R1388-1392.
44. Kalk P, Thöne-Reineke C, Schwartz A etal. Renal phenotype of ET-1 transgenic mice is modulated by androgens. Eur J Med Res 2009;14:55-58.
45. Agarwal R. Chronic kidney disease is associated with oxidative stress independent of hypertension. Clin Nephrol 2004;61:377-383.
46. Ide T, Tsutsui H, Ohashi N etal. Greater oxidative stress in healthy young man compared with premenopausal women. Arterioscler Thromb Vasc Biol 2002;22:438-442.
47. Kaehler J, Sill B, Koester R etal. Endothelin-1 mRNA and protein in vascular wall cells is increased by reactive oxygen species. Clin Sci (Lond) 2002;103(Suppl 48):176S-178.
48. Müller V, Szabo A, Vicklicky O etal. Sex hormones and gender-related differences: their influence on chronic renal allograft rejection. Kidney Int 1999;55:2011-2020.
49. Liu B, Ely D. Testosterone increases sodium reabsorption, blood pressure, and renal pathology in female spontaneously hypertensive rats on a high sodium diet. Adv Pharmacol Sci 2011;2011:817835.
50. Hewitson TD, Zhao C, Wigg B etal. Relaxin and castration in male mice protect from, but testosterone exacerbates, age-related cardiac and renal fibrosis, whereas estrogens are an independent determinant of organ size. Endocrinology 2012;153:188-199.
51. Verzola D, Villago B, Procopio V etal. Androgen-mediated by apoptosis of kidney tubule cells: role of c-jun amino terminal kinase. Biochem Biophys Res Commun 2009;387:531-536.
52. D'Agostino P, Milano S, Barbera C etal. Sex hormones modulate inflammatory mediators produced by macrophages. Ann N Y Acad Sci 1999;876:426-429.
53. Li ZG, Danis VA, Brooks PM. Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vivo. Clin Exp Rheumatol 1993;11:157-162.
54. Gornstein RA, Lapp CA, Bustos-Valdes SM, Zamorano P. Androgens modulate interleukin-6 production by gingival fibroblasts in vitro. J Periodontol 1999;70:604-609.
55. Culig Z. Androgen receptor cross-talk with cell-signaling pathways. Growth Factors 2004;22:179-184.
56. Delfino FJ, Boustead JN, Fix C, Walker WH. NF-κB and TNF-α stimulate androgen receptor expression in Sertoli cells. Mol Cell Endocrinol 2003;201:1-12.
57. Doublier S, Lupia E, Catanuto P etal. Testosterone and 17β- estradiol have opposite effects on podocyte apoptosis that precedes glomerulosclerosis in female estrogen receptor knockout mice. Kidney Int 2011;79:404-413.
58. Hall YN, Fuentes EF, Chertow GM, Olson J. Race/ethnicity and disease activity in IgA nephropathy. BMC Nephrol 2004;5:10.
59. Terada N, Arai Y, Kinukawa N, Yoshimura K, Terai A. Risk factors for renal cysts. BJU Int 2004;93:1300-1302.
60. Donadio JV Jr, Torres VE, Velosa JA etal. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 1988;33:708-715.
61. Pawluczyk IZ, Tan EK, Harris KP. Rat mesangial cells exhibit sex-specific profibrotic and proinflammatory phenotypes. Nephrol Dial Transplant 2009;24:1753-1758.
62. Mangili R, Deferrari G, Di Mario U etal. Arterial hypertension and microalbuminuria in IDDM: the Italian Microalbuminuria Study. Diabetologia 1994;37:1015-1024.
63. Jacobsen P, Rossing K, Tarnow L etal. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int Suppl 1999;71:S101-105.
64. Maric C, Forsblom C, Thorn L, Waden J, Groop PH, Finn Diane Study Group. Association between testosterone, estradiol and sex hormone binding globulin levels in men with type 1 diabetes with nephropathy. Steroids 2010;75:772-778.
65. Manigrasso MB, Sawyer RT, Marbury DC, Flynn ER, Maric C. Inhibition of estradiol synthesis attenuates renal injury in malestreptozotocin-induced diabetic rats. Am J Physiol Renal Physiol 2011;301:F634-640.
66. Manigrasso MB, Sawyer RT, Hutchens ZM Jr, Flynn ER, Maric-Bilkan C. Combined inhibition of aromatase activity and dihydrotestosterone supplementation attenuates renal injury in male streptozotocin (STZ)-induced diabetic rats. Am J Physiol Renal Physiol 2012;302:F1203-1209.
67. Xu Q, Prabhu A, Xu S, Manigrasso MB, Maric C. Dose-dependent effects of dihydrotestosterone in the streptozocin-induced diabetic rat kidney. Am J Physiol Renal Physiol 2009;297:F307-315.
68. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 2002;25:859-864.
69. Stehman-Breen CO, Sherrard DJ, Alem AM etal. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000;58:2200-2205.
70. Alem AM, Sherrard DJ, Gillen DL etal. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000;58:396-399.
71. Ishani A, Paudel M, Taylor BC etal. Renal function and rate of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Osteoporos Int 2008;19:1549-1556.
72. Lindberg JS, Moe S. Osteoporosis in end-stage renal disease. Semin Nephrol 1999;19:115-122.
73. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-882.
74. Berger C, Langsetmo L, Joseph L etal. Change in bone mineral density as a function of age in women and men and association with the antiresorptive agents. CMAJ 2008;178:1660-1668.
75. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000;106:1553-1560.
76. Seeman E, Melton LJ, O'Fallon WM, Riggs BL. Risk factor for spinal osteoporosis in men. Am J Med 1983;75:977-983.
77. Francis RM, Peacock M, Marshal DH, Horsman A, Aaron JE. Spinal osteoporosis in men. Bone Miner 1989;5:347-357.
78. Baillie SP, Davison CE, Johnson FJ, Francis RM. Pathogenesis of vertebral crush fractures in men. Age Ageing 1992;21:139-141.
79. Vanderschueren D, Bouillon R. Androgens and bone. Calcif Tissue Int 1995;56:341-346.
80. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 2004;25:389-425.
81. Huber DM, Bendixen AC, Pathrose P etal. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 2001;142:3800-3808.
82. Vanderschueren D, Van Herck E, Suiker AM, Visser WJ, Schot LP, Bouillon R. Bone and mineral metabolism in aged male rats: short and long effects of androgen deficiency. Endocrinology 1992;130:2906-2916.
83. Coxam V, Bowman BM, Mecham M, Roth CM, Miller MA, Miller SC. Effect of dihydrotestosterone alone and combined with estrogen on bone mineral density, bone growth, and formation rates in ovariectomized rats. Bone 1996;19:107-114.
84. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359:1841-1850.
85. Kohno K, Inaba M, Okuno S etal. Association of reduction in bone mineral density with mortality in male hemodialysis patients. Calcif Tissue Int 2009;84:180-185.
86. Doumouchtsis KK, Kostakis AI, Doumouchtsis SK etal. The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of RANKL. Hemodial Int 2008;12:100-107.
87. Tracz MJ, Sideras K, Bolona ER etal. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006;91:2011-2016.
88. Anderson FH, Francis RM, Peaston RT, Wastell HJ. Androgens supplementation in eugonadal men with osteoporosis: effect of six months' treatment on markers of bone formation and resorption. J Bone Miner Res 1997;12:472-478.
89. Locatelli F, Pozzoni P, Del Vecchio L. Anemia and heart failure in chronic kidney disease. Semin Nephrol 2005;25:392-396.
90. Parker JP, Beime GJ, Desai JN, Raich PC, Shahidi NT. Androgen-induced increase in red-cell 2, 3-diphosphoglycerate. N Engl J Med 1972;287:381-383.
91. Wiliamson CS. Influence of age and sex on hemoglobin: a spectrophotometric analysis of nine hundred and nineteen cases. Arch Intern Med 1916;18:505-528.
92. Vahlquist B. The cause of sex differences in erythrocyte hemoglobin and serum iron levels in human adults. Blood 1950;5:874-875.
93. Dickerman RD, Pertusi R, Miller J, Zachariah NY. Androgens induce erythrocytosis: is it erythropoietin? Am J Hematol 1999;61:154-155.
94. Moriyama Y, Fischer JW. Increase in erythroid colony formation in rabbits following the administration of testosterone. Proc Soc Exp Biol Med 1975;149:178-180.
95. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991;17:29-33.
96. Buttner R, Bollheimer LC, Zietz B etal. Definition and characterization of relative hypo- and hyperleptinemia in a large Caucasian population. J Endocrinol 2002;175:745-756.
97. Bachman E, Feng R, Travison T etal. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone induced erythrocytosis. J Clin Endocrinol Metab 2010;95:4743-4747.
98. Shaldon S, Koch KM, Oppermann F, Patyna WD, Schoeppe W. Testosterone therapy for anemia in maintenance dialysis. Br Med J 1971;3:212-215.
99. von-Hartitzsch B, Kerr DN, Morley G, Marks B. Androgens in the anemia of chronic renal failure. Nephron 1977;18:13-20.
100. Schustack A, Meshiaj D, Waiss Z, Gotloib L. Intramuscular iron replenishment and replacement combined with testosterone enanthate in maintenance hemodialysis anemia: a follow up to 8 years on 16 patients. Clin Nephrol 1985;23:303-306.
101. De Long M, Logan JL, Yong KC, Lien YH. Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance. Nephrol Dial Transplant 2005;20:585-590.
102. Grossmann M, Panagiotopoulou S, Sharpe K etal. Low testosterone and anemia in men with type 2 diabetes. Clin Endocrinol (Oxf) 2009;70:547-553.
103. Bathia V, Chaudhuri A, Tomar R, Dhindsa S, Ghanim H, Dandona P. Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care 2006;29:2289-2294.
104. Brockenbrough AT, Dittrich MO, Page ST, Smith T, Stivelman JC, Bremner WJ. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis 2006;47:251-262.
105. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012;2:279-335.
106. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003;24:313-340.
107. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75.
108. Khaw K, Dowsett M, Folkerd E etal. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007;116:2694-2701.
109. Corona G, Rastrelli G, Monami M etal. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011;165:687-701.
110. Fahed AC, Gholmieh JM, Azar ST. Connecting the lines between hypogonadism and atherosclerosis. Int J Endocrinol 2012;2012:793953.
111. Cheung AK, Sarnak MJ, Yan G etal. Cardiac disease in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004;65:2380-2389.
112. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
113. Carrero JJ, Stenvinkel P. Inflammation in end stage renal disease-what have we learned in 10 years? Semin Dial 2010;23:498-509.
114. Karakitsos D, Patrianakos AP, De Groot E etal. Androgen deficiency and endothelial dysfunction in men with end-stage kidney disease receiving maintenance hemodialysis. Am J Nephrol 2006;26:536-543.
115. Haring R, Nauck M, Völzke H etal. Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy. Am J Nephrol 2011;33:209-217.
116. Meng J, Ohlsson C, Laughlin GA etal. Associations of estradiol and testosterone with serum phosphorus in older men: the Osteoporotic Fractures in Men study. Kidney Int 2010;78:415-422.
117. Kestenbaum B, Sampson JN, Rudser KD etal. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528.
118. Majdan M, Kotarski J, Ksiazek A, Grzebalska A. Relationship between some prognostics marker of HD patients and serum erythropoietin, insulin-like growth factor-1, leptin, parathormone and testosterone. Int Urol Nephrol 1999;31:563-569.
119. Gungor O, Kircelli F, Carrero JJ etal. Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging? Clin J Am Soc Nephrol 2010;5:2018-2023.
120. Batrinos ML. The aging of the endocrine hypothalamus and its dependent endocrine glands. Hormones (Athens) 2012;11:241-253.
121. Carrero JJ, Qureshi AR, Nakashima A etal. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant 2011;26:184-190.
122. Kyriazis J, Tzanakis I, Stylianou K etal. Low testosterone, arterial stiffness and mortality in male haemodialysis patients. Nephrol Dial Transplant 2011;26:2971-2977.
123. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998;32(5 Suppl 3):112S-119.
124. Zoccali C. Endothelial dysfunction and the kidney: emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. J Am Soc Nephrol 2006;17(4 Suppl 2):61S-63.
125. Nanayakkara PW, Gaillard CA. Vascular disease and chronic renal failure: new insights. Neth J Med 2010;68:5-14.
126. Iglesias P, Carrero JJ, Diez JJ. Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutical options. J Nephrol 2012;25:31-42.
127. Carrero JJ, Stenvinkel P. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transplant 2012;27:4030-4041.
128. Toma M, McAlister FA, Coglianese EE etal. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 2012;5:315-321.
129. Laughlin GA, Goodell V, Barrett-Conor E. Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J Clin Endocrinol Metab 2010;95:740-747.